Skip to content
10-Q

Quarterly Report

CTI BIOPHARMA CORP

0000891293-22-000026

← back to feed
Filed
May 12, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 5, 2022 108.97M sh
Short Term Debt Q1 2022 · Mar 31, 2022 $47.52M
Short Term Debt Q1 2022 · Dec 31, 2021 $47.38M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $96.9M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $65.45M
Stockholders Equity Q1 2022 · Mar 31, 2022 −$27.92M
Stockholders Equity Q1 2022 · Dec 31, 2021 $3.77M
Current Liabilities Q1 2022 · Mar 31, 2022 $98.93M
Current Liabilities Q1 2022 · Dec 31, 2021 $66.65M
Total Liabilities Q1 2022 · Mar 31, 2022 $159.35M
Total Liabilities Q1 2022 · Dec 31, 2021 $68.67M
Current Assets Q1 2022 · Mar 31, 2022 $103.28M
Current Assets Q1 2022 · Dec 31, 2021 $68.38M
Total Assets Q1 2022 · Mar 31, 2022 $131.44M
Total Assets Q1 2022 · Dec 31, 2021 $72.43M
Shares Diluted Q1 2022 · Mar 31, 2021 76.37M sh
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$16.78M
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.23
Eps Basic Q1 2022 · Mar 31, 2021 −$0.23
Sga Expense Q1 2022 · Mar 31, 2021 $7.63M
Net Income Q1 2022 · Mar 31, 2021 −$17.27M
Operating Income Q1 2022 · Mar 31, 2021 −$17.07M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $0
Revenue Q1 2022 · Mar 31, 2021 $0